User menu

Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015

Bibliographic reference Astermark, Jan ; Hart, Dan ; Lobet, Sébastien ; Blatný, Jan ; d'Oiron, Roseline ; et. al. Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015. In: European Journal of Haematology, Vol. 97, no.Suppl. 84, p. 3-23 (2016)
Permanent URL http://hdl.handle.net/2078.1/175616
  1. UK National Haemophilia Database Bleeding Disorder Statistics for 2014-2015 http://www.ukhcdo.org/docs/AnnualReports/2015/UK_Bleeding_Disorder_Statistics_April%202014toMarch_2015ForWebsite.pdf
  2. Hay C. R. M., Purchasing factor concentrates in the 21st century through competitive tendering, 10.1111/hae.12169
  3. World Federation of Haemophilia Report - Annual Global Survey 2013 http://www1.wfh.org/publications/files/pdf-1591.pdf
  4. Giangrande, J Thromb Haemost, 13, 1 (2015)
  5. Konkle B. A., Stasyshyn O., Chowdary P., Bevan D. H., Mant T., Shima M., Engl W., Dyck-Jones J., Fuerlinger M., Patrone L., Ewenstein B., Abbuehl B., Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A, 10.1182/blood-2015-03-630897
  6. Mahdi Ali J., Obaji Samya G., Collins Peter W., Role of enhanced half-life factor VIII and IX in the treatment of haemophilia, 10.1111/bjh.13360
  7. Mahlangu J., Powell J. S., Ragni M. V., Chowdary P., Josephson N. C., Pabinger I., Hanabusa H., Gupta N., Kulkarni R., Fogarty P., Perry D., Shapiro A., Pasi K. J., Apte S., Nestorov I., Jiang H., Li S., Neelakantan S., Cristiano L. M., Goyal J., Sommer J. M., Dumont J. A., Dodd N., Nugent K., Vigliani G., Luk A., Brennan A., Pierce G. F., , Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A, 10.1182/blood-2013-10-529974
  8. Tiede A., Brand B., Fischer R., Kavakli K., Lentz S. R., Matsushita T., Rea C., Knobe K., Viuff D., Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A, 10.1111/jth.12161
  9. Turecek, Hamostaseologie, 32, S29 (2012)
  10. Young G., Mahlangu J., Kulkarni R., Nolan B., Liesner R., Pasi J., Barnes C., Neelakantan S., Gambino G., Cristiano L. M., Pierce G. F., Allen G., Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A, 10.1111/jth.12911
  11. Uchida N., Sambe T., Yoneyama K., Fukazawa N., Kawanishi T., Kobayashi S., Shima M., A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects, 10.1182/blood-2015-06-650226
  12. Sehgal Alfica, Barros Scott, Ivanciu Lacramioara, Cooley Brian, Qin June, Racie Tim, Hettinger Julia, Carioto Mary, Jiang Yongfeng, Brodsky Josh, Prabhala Harsha, Zhang Xuemei, Attarwala Husain, Hutabarat Renta, Foster Don, Milstein Stuart, Charisse Klaus, Kuchimanchi Satya, Maier Martin A, Nechev Lubo, Kandasamy Pachamuthu, Kel'in Alexander V, Nair Jayaprakash K, Rajeev Kallanthottathil G, Manoharan Muthiah, Meyers Rachel, Sorensen Benny, Simon Amy R, Dargaud Yesim, Negrier Claude, Camire Rodney M, Akinc Akin, An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia, 10.1038/nm.3847
  13. Clinical Trials https://clinicaltrials.gov/ct2/show/NCT02576795?term=biomarin+gene+therapy&26rank=1
  14. Nathwani Amit C., Tuddenham Edward G.D., Rangarajan Savita, Rosales Cecilia, McIntosh Jenny, Linch David C., Chowdary Pratima, Riddell Anne, Pie Arnulfo Jaquilmac, Harrington Chris, O'Beirne James, Smith Keith, Pasi John, Glader Bertil, Rustagi Pradip, Ng Catherine Y.C., Kay Mark A., Zhou Junfang, Spence Yunyu, Morton Christopher L., Allay James, Coleman John, Sleep Susan, Cunningham John M., Srivastava Deokumar, Basner-Tschakarjan Etiena, Mingozzi Federico, High Katherine A., Gray John T., Reiss Ulrike M., Nienhuis Arthur W., Davidoff Andrew M., Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B, 10.1056/nejmoa1108046
  15. Nathwani Amit C., Reiss Ulreke M., Tuddenham Edward G.D., Rosales Cecilia, Chowdary Pratima, McIntosh Jenny, Della Peruta Marco, Lheriteau Elsa, Patel Nishal, Raj Deepak, Riddell Anne, Pie Jun, Rangarajan Savita, Bevan David, Recht Michael, Shen Yu-Min, Halka Kathleen G., Basner-Tschakarjan Etiena, Mingozzi Federico, High Katherine A., Allay James, Kay Mark A., Ng Catherine Y.C., Zhou Junfang, Cancio Maria, Morton Christopher L., Gray John T., Srivastava Deokumar, Nienhuis Arthur W., Davidoff Andrew M., Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B, 10.1056/nejmoa1407309
  16. Isarangkura, Southeast Asian J Trop Med Public Health, 18, 552 (1987)
  17. Chuansumrit, Southeast Asian J Trop Med Public Health, 24, 174 (1993)
  18. Chuansumrit, Southeast Asian J Trop Med Public Health, 26, 243 (1995)
  19. Daliri Aliasghar Ahmad Kia, Haghparast Hassan, Mamikhani Jahanara, Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran, 10.1017/s0266462309990420
  20. Gouider E., Rauchensteiner S., Andreeva T., Al Zoebie A., Mehadzic S., Nefyodova L., Brunn M., Tueckmantel C., Meddeb B., Real-life evidence in evaluating effectiveness of treatment in Haemophilia A with a recombinant FVIII concentrate: A non-interventional study in emerging countries, 10.1111/hae.12631
  21. WU R., LUKE K.-H., POON M.-C., WU X., ZHANG N., ZHAO L., SU Y., ZHANG J., Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China : LOW DOSE SECONDARY PROPHYLAXIS IN HAEMOPHILIA, 10.1111/j.1365-2516.2010.02348.x
  22. Tang L., Wu R., Sun J., Zhang X., Feng X., Zhang X., Luke K.-H., Poon M.-C., Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China, 10.1111/j.1365-2516.2012.02926.x
  23. Rea Catherine J., Foley Jonathan H., Bevan David H., Sørensen Benny, An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A, 10.1007/s00277-013-1921-z
  24. Nuvvula Sivakumar, Gaddam KumarRaja, Kamatham Rekhalakshmi, Efficacy of tranexamic acid mouthwash as an alternative for factor replacement in gingival bleeding during dental scaling in cases of hemophilia: A randomized clinical trial, 10.4103/0976-237x.128663
  25. EHC website http://wordpress.ehc.eu/wp-content/uploads/2014/11/Rapport-09-2014LR.pdf
  26. Lauersen Jeppe Bo, Bertelsen Ditte Marie, Andersen Lars Bo, The effectiveness of exercise interventions to prevent sports injuries: a systematic review and meta-analysis of randomised controlled trials, 10.1136/bjsports-2013-092538
  27. Negrier C., Seuser A., Forsyth A., Lobet S., Llinas A., Rosas M., Heijnen L., The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity, 10.1111/hae.12118
  28. Czepa D., von Mackensen S., Hilberg T., Haemophilia & Exercise Project (HEP): The impact of 1-year sports therapy programme on physical performance in adult haemophilia patients, 10.1111/hae.12031
  29. Buxbaum, Haemophilia, 16, 656 (2010)
  30. Schoenmakers M. A. G. C., Gulmans V. A. M., Helders P. J. M., Van Den Berg H. M., Motor performance and disability in Dutch children with haemophilia: a comparison with their healthy peers, 10.1046/j.1365-2516.2001.00504.x
  31. Nader Philip R., Moderate-to-Vigorous Physical Activity From Ages 9 to 15 Years, 10.1001/jama.300.3.295
  32. DOUMA-VAN RIET D. C. M., ENGELBERT R. H. H., VAN GENDEREN FRANK R., TER HORST-DE RONDE MANON T. M., DE GOEDE-BOLDER ARJA, HARTMAN ANNELIES, Physical fitness in children with haemophilia and the effect of overweight, 10.1111/j.1365-2516.2008.01928.x
  33. BIERE-RAFI S., HAAK B. W., PETERS M., GERDES V. E. A., BÜLLER H. R., KAMPHUISEN P. W., The impairment in daily life of obese haemophiliacs : THE IMPAIRMENT IN DAILY LIFE OF OBESE HAEMOPHILIACS, 10.1111/j.1365-2516.2010.02417.x
  34. SCUDDER MARK R., LAMBOURNE KATE, DROLLETTE ERIC S., HERRMANN STEPHEN D., WASHBURN RICHARD A., DONNELLY JOSEPH E., HILLMAN CHARLES H., Aerobic Capacity and Cognitive Control in Elementary School-Age Children : , 10.1249/mss.0000000000000199
  35. Kettunen Jyrki A., Kujala Urho M., Exercise therapy for people with rheumatoid arthritis and osteoarthritis, 10.1111/j.1600-0838.2004.00396.x
  36. Metsios G. S., Stavropoulos-Kalinoglou A., Veldhuijzen van Zanten J. J. C. S., Treharne G. J., Panoulas V. F., Douglas K. M. J., Koutedakis Y., Kitas G. D., Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review, 10.1093/rheumatology/kem260
  37. WFH Life Expectancy www.wfh.org/en/page.aspx?pid=637#Life_Expectancy
  38. Cruz-Díaz David, Lomas Vega Rafael, Osuna-Pérez Maria Catalina, Hita-Contreras Fidel, Martínez-Amat Antonio, Effects of joint mobilization on chronic ankle instability: a randomized controlled trial, 10.3109/09638288.2014.935877
  39. Kujala U M, Evidence on the effects of exercise therapy in the treatment of chronic disease, 10.1136/bjsm.2009.059808
  40. Lui, Aust J Ageing, 29, 98 (2009)
  41. Astermark J., Dolan G., Hilberg T., Jiménez-Yuste V., Laffan M., Lassila R., Lobet S., Martinoli C., Perno C.-F., Managing Haemophilia for Life: 4th Haemophilia Global Summit, 10.1111/hae.12468
  42. Hilberg T., Herbsleb M., Puta C., Gabriel H. H. W., Schramm W., Physical training increases isometric muscular strength and proprioceptive performance in haemophilic subjects, 10.1046/j.1365-2516.2003.00679.x
  43. Rondanelli Mariangela, Faliva Milena, Monteferrario Francesca, Peroni Gabriella, Repaci Erica, Allieri Francesca, Perna Simone, Novel Insights on Nutrient Management of Sarcopenia in Elderly, 10.1155/2015/524948
  44. Cermak N. M., Res P. T., de Groot L. C., Saris W. H., van Loon L. J., Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis, 10.3945/ajcn.112.037556
  45. Denison, Clin Interv Aging, 10, 859 (2015)
  46. EMA CHMP www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109692.pdf
  47. International Society for Pharmacoeconomics and Outcomes Research www.ispor.org/news/articles/oct07/rld.asp
  48. DIMICHELE D. M., BLANCHETTE V., BERNTORP E., Clinical trial design in haemophilia : CLINICAL TRIAL DESIGN IN HAEMOPHILIA, 10.1111/j.1365-2516.2012.02824.x
  49. RAGNI M. V., MOORE C. G., BIAS V., KEY N. S., KOUIDES P. A., FRANCIS C. W., , Challenges of rare disease research: limited patients and competing priorities : CHALLENGES OF RARE DISEASE RESEARCH, 10.1111/j.1365-2516.2011.02646.x
  50. Calvez T., Chambost H., Claeyssens-Donadel S., d'Oiron R., Goulet V., Guillet B., Heritier V., Milien V., Rothschild C., Roussel-Robert V., Vinciguerra C., Goudemand J., , Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A, 10.1182/blood-2014-07-586347
  51. Collins P. W., Palmer B. P., Chalmers E. A., Hart D. P., Liesner R., Rangarajan S., Talks K., Williams M., Hay C. R. M., , Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011, 10.1182/blood-2014-07-580498
  52. Hay C. R. M., Palmer B. P., Chalmers E. A., Hart D. P., Liesner R., Rangarajan S., Talks K., Williams M., Collins P. W., , The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison, 10.1111/hae.12563
  53. COLVIN B. T., ASTERMARK J., FISCHER K., GRINGERI A., LASSILA R., SCHRAMM W., THOMAS A., INGERSLEV J., , European principles of haemophilia care, 10.1111/j.1365-2516.2007.01625.x
  54. Evatt B World Federation of Hemophilia Guide to Developing a National Patient Registry www1.wfh.org/publication/files/pdf-1288.pdf
  55. CNHP registry website www.registry.cz/index-en.php?pg=registries&26prid=43
  56. CNHP website http://cnhp.registry.cz/
  57. EUHASS background www.euhass.org/background.html
  58. EUHASS participants www.euhass.org/participants.html
  59. EUHASS methodology www.euhass.org/methodology.html
  60. EUHASS results www.euhass.org/results.html
  61. ABPI vision for real-world data www.abpi.org.uk/our-work/library/industry/documents/vision-for-real-world-data.pdf
  62. Srivastava A., Brewer A. K., Mauser-Bunschoten E. P., Key N. S., Kitchen S., Llinas A., Ludlam C. A., Mahlangu J. N., Mulder K., Poon M. C., Street A., , Guidelines for the management of hemophilia, 10.1111/j.1365-2516.2012.02909.x
  63. Makris, Blood Transfus, 10, 165 (2012)
  64. MANCUSO M. E., GRACA L., AUERSWALD G., SANTAGOSTINO E., Haemophilia care in children - benefits of early prophylaxis for inhibitor prevention, 10.1111/j.1365-2516.2008.01947.x
  65. Blanchette V. S., Key N. S., Ljung L. R., Manco-Johnson M. J., van den Berg H. M., Srivastava A., , Definitions in hemophilia: communication from the SSC of the ISTH, 10.1111/jth.12672
  66. Oldenburg J., Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens, 10.1182/blood-2015-01-528414
  67. Khawaji Mohammed, Astermark Jan, Berntorp Erik, Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life : Lifelong prophylaxis in patients with haemophilia, 10.1111/j.1600-0609.2012.01750.x
  68. Tagliaferri A., Feola G., Molinari A. C., Santoro C., Rivolta G. F., Cultrera D. B., Gagliano F., Zanon E., Mancuso M. E., Valdré L., Mameli L., Amoresano S., Mathew P., Coppola A., POTTER Study Group for the, , Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study : , 10.1160/th14-05-0407
  69. NILSSON I. M., BERNTORP E., LÖFQVIST T., PETTERSSON H., Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B, 10.1111/j.1365-2796.1992.tb00546.x
  70. van den Berg H. M., Fischer K., Mauser-Bunschoten E. P., Beek F. J. A., Roosendaal G., van der Bom J. G., Nieuwenhuis H. K., Long-term outcome of individualized prophylactic treatment of children with severe haemophilia, 10.1046/j.1365-2141.2001.02580.x
  71. FELDMAN B. M., PAI M., RIVARD G. E., ISRAELS S., POON M.-C., DEMERS C., ROBINSON S., LUKE K.-H., WU J. K. M., GILL K., LILLICRAP D., BABYN P., MCLIMONT M., BLANCHETTE V. S., , Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study, 10.1111/j.1538-7836.2006.01953.x
  72. Iorio Alfonso, Carcao Manuel, Individualizing Factor Replacement Therapy in Severe Hemophilia, 10.1055/s-0035-1552563
  73. Nijdam A., Kurnik K., Liesner R., Ljung R., Nolan B., Petrini P., Fischer K., , How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access, 10.1111/hae.12613
  74. KURNIK K., BIDLINGMAIER C., ENGL W., CHEHADEH H., REIPERT B., AUERSWALD G., New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development : NEW REGIMEN CAN REDUCE INHIBITOR DEVELOPMENT, 10.1111/j.1365-2516.2009.02122.x
  75. Santagostino Elena, Mancuso Maria Elisa, Rocino Angiola, Mancuso Giacomo, Mazzucconi Maria Gabriella, Tagliaferri Annarita, Messina Maria, Mannucci Pier Mannuccio, Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study, 10.1111/j.1365-2141.2005.05605.x
  76. Ratain MJ Plunkett WK Principles of Pharmacokinetics
  77. Lindsay M Characterization of Post-translational Modifications and Resulting Structure/Function Relationships of Recombinant Human Factor IX Produced in the Milk of Transgenic Pigs https://theses.lib.vt.edu/theses/available/etd-12212004-143333/unrestricted/Chapter5-Pharmacokinetics.pdf
  78. COLLINS P. W., FISCHER K., MORFINI M., BLANCHETTE V. S., BJÖRKMAN S., , Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia : PHARMACOKINETICS AND PROPHYLAXIS, 10.1111/j.1365-2516.2010.02370.x
  79. BJÖRKMAN S., BLANCHETTE V. S., FISCHER K., OH M., SPOTTS G., SCHROTH P., FRITSCH S., PATRONE L., EWENSTEIN B. M., COLLINS P. W., , Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring, 10.1111/j.1538-7836.2010.03757.x
  80. Björkman S., Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy, 10.1111/hae.12216
  81. Morfini, Blood Transfus, 6, s21 (2008)
  82. COLLINS P. W., BLANCHETTE V. S., FISCHER K., BJÖRKMAN S., OH M., FRITSCH S., SCHROTH P., SPOTTS G., ASTERMARK J., EWENSTEIN B., , Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A, 10.1111/j.1538-7836.2008.03270.x
  83. COLLINS P. W., BJÖRKMAN S., FISCHER K., BLANCHETTE V., OH M., SCHROTH P., FRITSCH S., CASEY K., SPOTTS G., EWENSTEIN B. M., Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens, 10.1111/j.1538-7836.2009.03703.x
  84. Collins PW Oral communicated presented at the 2012 WFH congress
  85. ISTH summary statement, Haemophilia, 4, 3 (2006)
  86. BJÖRKMAN S., COLLINS P., , Measurement of factor VIII pharmacokinetics in routine clinical practice : Factor VIII pharmacokinetics, 10.1111/jth.12055
  87. WAPPS Project https://plus.mcmaster.ca/wapps-hemo/
  88. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT02061072
  89. Smartpatients website www.smartpatients.com/trials/NCT02061072
  90. Shapiro A. D., Korth-Bradley J., Poon M.-C., Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia, 10.1111/j.1365-2516.2005.01149.x
  91. Berntorp E., Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study, 10.1111/hae.12277
  92. Plug I., Peters M., Mauser-Bunschoten E. P., de Goede-Bolder A., Heijnen L., Smit C., Willemse J., Rosendaal F. R., van der Bom J. G., Social participation of patients with hemophilia in the Netherlands, 10.1182/blood-2007-07-102202
  93. Varekamp I., Smit C., Rosendaal F.R., Bröcker-Vriends A., Briët E., van Dijck H., Suurmeijer T.P.B.M., Employment of individuals with haemophilia in the Netherlands, 10.1016/0277-9536(89)90269-4
  94. Holstein Katharina, Eifrig Barbara, Langer Florian, Relationship between haemophilia and social status, 10.1016/j.thromres.2013.10.012
  95. WFH Guidelines for the management of haemophilia http://www.wfh.org/publication/files/pdf-1472.pdf
  96. Srivastava A., Haemophilia care - beyond the treatment guidelines, 10.1111/hae.12429
  97. Fischer K., Steen Carlsson K., Petrini P., Holmstrom M., Ljung R., van den Berg H. M., Berntorp E., Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s, 10.1182/blood-2012-12-470898
  98. Reipert, Hematology Am Soc Hematol Educ Program, 2014, 372 (2014)
  99. Klein Ludger, Kyewski Bruno, Allen Paul M., Hogquist Kristin A., Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see), 10.1038/nri3667
  100. Hofbauer C. J., Whelan S. F. J., Hirschler M., Allacher P., Horling F. M., Lawo J.-P., Oldenburg J., Tiede A., Male C., Windyga J., Greinacher A., Knobl P. N., Schrenk G., Koehn J., Scheiflinger F., Reipert B. M., Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans, 10.1182/blood-2014-09-598268
  101. TER AVEST P. C., FISCHER K., MANCUSO M. E., SANTAGOSTINO E., YUSTE V. J., VAN DEN BERG H. M., VAN DER BOM J. G., Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice, 10.1111/j.1538-7836.2008.03187.x
  102. Hashemi S. M., Fischer K., Moons K. G. M., van den Berg H. M., , Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A, 10.1111/hae.12566
  103. Astermark J., Donfield S. M., Gomperts E. D., Schwarz J., Menius E. D., Pavlova A., Oldenburg J., Kessing B., DiMichele D. M., Shapiro A. D., Winkler C. A., Berntorp E., , The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort, 10.1182/blood-2012-06-434803
  104. Oldenburg, Thromb Haemost, 77, 238 (1997)
  105. Hay, Thromb Haemost, 77, 234 (1997)
  106. Pashov A. D., Calvez T., Gilardin L., Maillère B., Repessé Y., Oldenburg J., Pavlova A., Kaveri S. V., Lacroix-Desmazes S., , In silicocalculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene, 10.1111/hae.12276
  107. Pradeu Thomas, Cooper Edwin L., The danger theory: 20 years later, 10.3389/fimmu.2012.00287
  108. Gouw S. C., van der Bom J. G., Marijke van den Berg H., , Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study, 10.1182/blood-2006-11-056291
  109. Auerswald G Kurnik K Blatny J Reininger AJ The EPIC Study: a clinical trial to assess whether early low dose prophylaxis in the absence of immunological danger signals reduces inhibitor incidence in previously untreated patients (PUPs) with haemophilia A.55th ASH Annual Meeting and Exposition
  110. Goudemand J Rothschild C d'Oiron R et al Plasma-derived factor VIII products and inhibitor development in previously untreated boys with severe haemophilia A: report of the francecoag network. Oral communication
  111. Peyvandi F Mannucci PM Garagiola I Elalfy E El-Beshlawy A Ramanan MV Source of factor VIII replacement (plasmatic or recombinant) and incidence of inhibitory alloantibodies in previously untreated patients with severe haemophilia A: The multicentre randomized sippet study
  112. IORIO A., HALIMEH S., HOLZHAUER S., GOLDENBERG N., MARCHESINI E., MARCUCCI M., YOUNG G., BIDLINGMAIER C., BRANDAO L. R., ETTINGSHAUSEN C. E., GRINGERI A., KENET G., KNÖFLER R., KREUZ W., KURNIK K., MANNER D., SANTAGOSTINO E., MANNUCCI P. M., NOWAK-GÖTTL U., Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review : Inhibitor rate after plasma-derived or recombinant FVIII concentrates, 10.1111/j.1538-7836.2010.03823.x
  113. Gouw Samantha C., van der Bom Johanna G., Ljung Rolf, Escuriola Carmen, Cid Ana R., Claeyssens-Donadel Ségolène, van Geet Christel, Kenet Gili, Mäkipernaa Anne, Molinari Angelo Claudio, Muntean Wolfgang, Kobelt Rainer, Rivard George, Santagostino Elena, Thomas Angela, van den Berg H. Marijke, Factor VIII Products and Inhibitor Development in Severe Hemophilia A, 10.1056/nejmoa1208024
  114. Fischer K., Lassila R., Peyvandi F., Calizzani G., Gatt A., Lambert T., Windyga J., Iorio A., Gilman E., Makris M., , Inhibitor development in haemophilia according to concentrate : Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project, 10.1160/th14-10-0826
  115. Vézina C., Carcao M., Infante-Rivard C., Lillicrap D., Stain A. M., Paradis E., Teitel J., Rivard G. E., , Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010, 10.1111/hae.12479
  116. Rivard G. E., Lillicrap D., Poon M. C., Demers C., Lepine M., St-Louis J., Warner M., Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?, 10.1111/j.1365-2516.2005.01088.x
  117. GARMAN R. D., MUNROE K., RICHARDS S. M., Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease, 10.1111/j.1365-2249.2004.02567.x
  118. Messinger Yoav H., Mendelsohn Nancy J., Rhead William, Dimmock David, Hershkovitz Eli, Champion Michael, Jones Simon A., Olson Rebecca, White Amy, Wells Cara, Bali Deeksha, Case Laura E., Young Sarah P., Rosenberg Amy S., Kishnani Priya S., Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease, 10.1038/gim.2011.4
  119. Moorehead PC Van VA Sponagle K Steinitz KN Reipert BM Lillicrap D Co-administration of factor VIII and dexamethasone prevents anti-factor VIII antibody development in a mouse model of hemophilia A